Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid ®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.

Sundar Jagannath, MD, Bill Bensinger, MD, Robert Vescio, MD, Elber Camacho, MD, Jeffrey Wolf, MD, David Irwin, MD, Gerardo Capo, MD, Marti McKinley, MD, David H. Vesole, MD, Amitabha Mazumder, MD, John Crowley, MD, Dixie Esseltine, MD, Brian Durie, MD

Blood (2007) 110 (11): 188.

https://doi.org/10.1182/blood.V110.11.188.188

Published: 2007

Journal Articles

Prospective Evaluation of the Bone Anabolic Effect of Bortezomib in Relapsed Multiple Myeloma (MM) Patients.

Maurizio Zangari, MD, Federica Cavallo, MD, Larry Suva, PhD, Joshua Dilley, Guido Trico, MD, Bart Barlogie, MD, Michael J. Burns, Roberto Passera, Mario Boccadoro, Dixie Esseltine, MD, Shmuel Yaccoby, PhD

Blood (2007) 110 (11): 2719.

https://doi.org/10.1182/blood.V110.11.2719.2719

Published: 2007

Journal Articles

Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin’s Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response.

John Gerecitano, MD, PhD, Andre Goy, MD, Barbara MacGregor-Cortelli, OCN, Ellen Neylon, John Wright, MD, PhD, Dixie Esseltine, MD, David Schenkein, MD, Mithat Gonen, PhD, Owen A. O’Connor, MD, PhD

Blood (2005) 106 (11): 3334.

https://doi.org/10.1182/blood.V106.11.3334.3334

Published: 2005

Journal Articles

Osteoblastic Activation and Response to Velcade® in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Maurizio Zangari, MD, Choon-Kee Lee, MD, Bart Barlogie, MD, PhD, Kevin Najarian, Seung-Hee Kang, MD, Shmuel Yaccoby, PhD, Dixie Esseltine, MD, FRCPC, Julie M. Stover, BA, Guido J. Tricot, MD, PhD

Blood (2004) 104 (11): 4910.

https://doi.org/10.1182/blood.V104.11.4910.4910

Published: 2004

Journal Articles

Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL.

Stefan Faderl, MD, Kanti R. Rai, MD, John Gribben, MD, Ian Flinn, MD, John C. Byrd, MD, David McConkey, PhD, David Schenkein, MD, Dixie Esseltine, MD, Mary L. Browning, RN, Michael J. Keating, MD

Blood (2004) 104 (11): 4841.

https://doi.org/10.1182/blood.V104.11.4841.4841

Published: 2004

NARROW

A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid ®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.

Prospective Evaluation of the Bone Anabolic Effect of Bortezomib in Relapsed Multiple Myeloma (MM) Patients.

Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin’s Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response.

Osteoblastic Activation and Response to Velcade® in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL.

Email alerts

ASH Publications

American Society of Hematology

A Phase II Study of Bortezomib (Velcade®), Cylophosphamide (Cytoxan®), Thalidomide (Thalomid ®) and Dexamethasone as First-Line Therapy for Multiple Myeloma.

Prospective Evaluation of the Bone Anabolic Effect of Bortezomib in Relapsed Multiple Myeloma (MM) Patients.

Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin’s Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response.

Osteoblastic Activation and Response to Velcade® in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Phase 2 Study of Three Doses of Single Agent Bortezomib in Patients with Fludarabine-Refractory B-Cell CLL.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only